RxDoctor Payments Data

Ariel Gonzalez Cordero, MD

Cardiovascular Disease · Carolina, PRNPI 1376924506

Payments from drug & device makers

$4,321in general payments, 2019–2025

Across 86 payments — averaging $50.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$932
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$550
  • AstraZeneca$163
  • Amgen$143
  • E.r. Squibb & Sons, L.L.C.$141
  • plus $347 from 7 others

What the payments were for

  • Food & beverage$4,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)19$2,045
Abbott11$932
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)26$550
AstraZeneca3$163
Amgen2$143
E.r. Squibb & Sons, L.L.C.11$141
Johnson & Johnson3$132
Bayer Puerto Rico Inc.3$63
PBG Puerto Rico LLC4$62
Eli Lilly Export S.A. Puerto Rico Branch1$25
Boehringer Ingelheim1$25
Scpharmaceuticals Inc.1$23
Novartis1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,321 in reported general payments places this provider in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$15,015
Medicare patients
82
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$56,280
FarxigaDapagliflozin Propanediol58$35,193
JardianceEmpagliflozin39$29,938
XareltoRivaroxaban27$21,125
Rosuvastatin Calcium235$2,355
Candesartan Cilexetil28$2,036
Losartan Potassium208$1,700
Metoprolol Succinate126$1,359
Atorvastatin Calcium150$1,120
Carvedilol110$765
Amlodipine Besylate149$679
Spironolactone59$601
Nifedipine ErNifedipine27$551
Ezetimibe32$461
Omega-3 Acid Ethyl Esters13$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$163$35,19358 claims
Boehringer IngelheimJardiance$25$29,93839 claims
Johnson & JohnsonXarelto$132$21,12527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Carolina

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →